Wockhardt shares jump 9% after strong Q4 turnaround, robust FY26 growthWockhardt shares saw a significant jump on Tuesday. The pharmaceutical company reported a strong turnaround in its March quarter performanc...
This time tailwinds for good and long term: 5 midcap pharma stocks where probably management has learnt the lessonPharma is one sector, where literally every company in the sector has gone through a phase where it is forced to have a look at its own bus...
Wockhardt shuts US manufacturing plantThe company expects the US plant shutdown and transfer of products from inhouse to third-party contract manufacturers to help save $12 mill...
Cipla, PAG eye Wockhardt’s formulations businessWockhardt employs more than 7,000 people and has a presence in the US, Britain, Ireland, Switzerland, France, Mexico, Russia and other coun...
Wockhardt back in the black, posts Q3 profit of Rs 19 croreWockhardt had posted a net loss of Rs 76.86 crore for the corresponding period of 2018-19.
Wockhardt rallies after revival plan gets a boost from drug nodInvestors cheered the news, sending Wockhardt’s shares up by 5.7 per cent on the BSE on Thursday.
Wockhardt gets DGCI approval for 2 new antibiotics"DCGI (Drug Controller General of India) has approved Wockhardt's two new antibiotics, EMROK (IV) and EMROK 0 (Oral), for acute bacterial s...